Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.78 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.55 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10175838 | 0.94 | PTGDR2 (0.82) | PTGDR2DHCR7PTGDR | |
| SCHEMBL841154 | 0.93 | PTGDR2 (0.77) | PTGDR2DHCR7PTGDRPKMOPRM1 | |
| SCHEMBL840801 | 0.90 | PTGDR2 (0.90) | PTGDR2DHCR7PTGDR | |
| SCHEMBL840906 | 0.88 | PTGDR2 (0.75) | PTGDR2DHCR7PTGDRPKM | |
| SCHEMBL10175763 | 0.88 | PTGDR2 (1.00) | PTGDR2DHCR7PTGDRPKM | |
| SCHEMBL863566 | 0.88 | PTGDR2 (0.81) | PTGDR2DHCR7PTGDRPKM | |
| SCHEMBL840264 | 0.87 | PTGDR2 (0.83) | PTGDR2DHCR7PTGDROPRM1OPRL1 | |
| SCHEMBL863373 | 0.86 | PTGDR2 (0.81) | PTGDR2DHCR7PTGDRPKM | |
| SCHEMBL10225941 | 0.85 | PTGDR2 (0.77) | PTGDR2DHCR7PTGDRPKM | |
| SCHEMBL863339 | 0.85 | PTGDR2 (0.77) | PTGDR2DHCR7PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623903-B2 | Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2014-01-07 | — | — | US | disclosed |
| US-20120142687-A1 | INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | KUGIMIYA AKIRA (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142687-A1 | INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, CYSLTR1, CYSLTR2 | PTGDR2 7/4885DHCR7 760/4885PTGDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.